A shining new hope in the fight against cancer.

For those diagnosed with advanced kidney cancer (ccRCC) or metastatic prostate cancer (mCRPC), the outlook can be bleak. Dr. Reinier Hernandez at the Advanced Radiotheranostics (ART) Lab at the University of Wisconsin-Madison School of Medicine knew that developing novel radiopharmaceutical therapies for precise radiation delivery was paramount.

The challenge: finding a dependable, highly pure source of n.c.a. Lu-177 to pair with Dr. Hernandez’s and WARF therapeutic team’s promising compounds.

READ ON TO LEARN MORE

100% survival

ACHIEVED IN PRECLINICAL MODELS OF KIDNEY CANCER AT A DOSE OF 1 mCi

Best-in-class

PROFILE WITH 55%IA/g TUMOR UPTAKE AT 24 HOURS

8-20x
greater efficacy

IN VIVO COMPARED TO OTHER COMPOUNDS IN DEVELOPMENT

BOOK A CALL

Illuminating the opportunities.

Without a reliable source of high-quality n.c.a. Lu-177, radiopharmaceutical therapies face reduced potency and efficacy, radiation safety concerns, increased costs, supply chain vulnerabilities and disruptions from international sourcing, and more.

Dr. Hernandez and his team chose SHINE Technologies’ highly pure Ilumira n.c.a. Lu-177 for their kidney and prostate cancer studies.

SHINE Technologies: A beacon of excellence.

Based in Janesville, Wisconsin and only 50 miles from the UW-Madison research labs, SHINE has the largest production facility for n.c.a. Lu-177. SHINE Technologies’ ability to provide a reliable, high-quality supply of n.c.a. Lu-177 via Ilumira enabled Dr. Hernandez to conduct his studies without concerns over quality or supply chain disruptions.

SHINE’s benefits:

Enhanced Research Speed
No delays waiting for international shipments or customs clearance
Improved Data Quality
Consistent n.c.a. Lu-177 purity leads to more reliable results
Increased Research Scope
Reliable supply allows for more extensive testing and optimization
Streamlined Regulatory Path
- Using the same high-quality n.c.a. Lu-177 from research through clinical trials simplifies the regulatory process

Powerful partnership.
Powerful results.

SHINE’s consistent, high-purity Ilumira Lu-177 supply allowed for precise dosing and reliable results, critical factors in developing these promising therapies and moving them toward clinical trials.

DOWNLOAD THE CASE STUDY

Kidney cancer study:

Achieved 100% survival in preclinical models of kidney cancer at a dose of 1 mCi

Best-in-class profile with 55%IA/g tumor uptake at 24 hours and 18%IA/g retention at 7 days

8-20x greater efficacy in vivo compared to other compounds in development

Prostate cancer study:

Approximately three times more n.c.a. Lu-177 reached the tumors and remained there for an extended period

Demonstrated superior tumor growth inhibition compared to existing treatments

Efficacy even at lower administered activities, potentially leading to reduced side effects for patients in future clinical applications

Shining a light on new paths forward.

SHINE Technologies’ ability to deliver n.c.a. Lu-177 with exceptional purity and reliability exemplifies how bridging the gap between cutting-edge research and dependable isotope production can accelerate medical breakthroughs.

Read the case study in its entirety.